Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
74 hedge funds and large institutions have $298M invested in Albireo Pharma Inc in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
9% more capital invested
Capital invested by funds: $273M → $298M (+$25.4M)
3% more funds holding
Funds holding: 72 → 74 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$24M |
| 2 |
Man Group
London,
United Kingdom
|
+$5.61M |
| 3 |
BlackRock
New York
|
+$2.83M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.63M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.52M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.5M |
| 3 |
AG
Artal Group
Luxembourg
|
-$1.67M |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$836K |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$664K |
ALBO Hedge Fund Activity: Q2 2019 in Review
74 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2019, worth a combined $298M — up 9.3% from $273M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ALBO positions and 6 closed out — a net gain of 4 holders — while 29 added to existing stakes and 18 trimmed.
The largest buyer was Federated Hermes, adding an estimated $24M. The largest seller was BVF Inc, cutting an estimated $4.52M.
- 74 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2019, up from 72 in Q1 2019.
- Funds reported $298M of Albireo Pharma Inc stock for Q2 2019, up 9.3% quarter-over-quarter.
- 10 funds opened new Albireo Pharma Inc positions in Q2 2019 and 6 closed out, a net change of +4 holders.
- The largest Albireo Pharma Inc buyer in Q2 2019 was Federated Hermes, an estimated $24M added.
- The largest Albireo Pharma Inc seller in Q2 2019 was BVF Inc, an estimated $4.52M sold.
Based on aggregated 13F filings for Q2 2019.